Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

Ortho Pharmaceutical Corporation

Other

The Scripps Research Institute

Johnson & Johnson Pharmaceutical Research & Development, LLC

Janssen Pharmaceuticals, Inc.

Timothy W Lovenberg

Nicholas I Carruthers

Mark G Erlander

Arne Huvar

Changlu Liu

Jayashree Pyati

Allen B Reitz

Ronald L Wolin

Scott L Dax

Xiaobing Li

Mark Andrew Youngman

Jill A Jablonowski

Cheryl P Kordik

Steven W Sutton

James J McNally

Wenying Chai

Dale A Rudolph

John M Keith

Kiev S Ly

Charles Q Huang

Richard Apodaca

Alejandro Santillán, Jr

Liu Y Tang

Pascal Bonaventure

Leslie A Gomez

Ann J Barbier

James Patrick Edwards

Todd Kevin Jones

Cheryl A Grice

John R Carson

Curt A Dvorak

William V Murray

Barbara A Pio

J Guy Breitenbucher

Jianmei Wei

Donald William Ludovici

Chandravadan R Shah

Haripada Khatuya

Wei Xiao

J Gregor Sutcliffe

Lars Karlsson

Ellen W Baxter

Mark Seierstad

Victor K Phuong

Robin L Thurmond

Wai-Ping Leung

Jiejun Wu

Laura C McAtee

Chi Luo

Annette K Kwok

Siquan Sun

Chester Kuei

Siguan Sun

Jennifer D Kreisberg

Michael Bogenstaetter

Diane Nepomuceno

Barbara Pio

Certain hexahydro-pyrrolo-isoquinoline compounds are histamine Hreceptor and serotonin transporter modulators useful in the treatment of histamine Hreceptor- and serotonin-mediated diseases.

Hexahydro-pyrrolo-isoquinoline compounds

Complexes of GPR81 receptor components and ligand components, such as L-lactate or GHB, may be used as an assay reagent for screening for modulators of GPR81 receptor activity.

Methods of identifying modulators of GPR81 receptors

The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

Aryl piperidine amides

Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.

Relaxin-3 chimeric polypeptides and their preparation and use

Canine 5-hydroxytryptamine 2 receptor materials are described, including polypeptides corresponding to SEQ ID NOs.:8 and 10 and polynucleotides expressing them corresponding to SEQ ID NOs.:7 and 9. Such materials are useful as reagents in drug screening assays to identify compounds having 5-HTreceptor-modulating activity.

Canine 5-hydroxytryptamine 2A and 2B receptor

The present invention provides a new method for identifying modulators of human orexin-2 receptor without utilizing recombinantly produced nucleic acid molecules encoding human orexin receptor protein. This method combines and utilizes known methods and cell lines selected for their natural expression of orexin-2 receptors to carry out the methods of the present invention. Exemplary methods of the present invention utilize PFSK-1 cells to produce non-recombinant human orexin-2 receptor protein.

Method for identifying modulators of human orexin-2 receptor

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

Non-peptidic NPY Y2 receptor inhibitors

The invention relates to novel 2-Oxy, 2-Amino, and 2-Thio-imidazole compounds of formula (I): 

2-oxy, 2-amino, and 2-thio-imidazole compounds

DNAs encoding the mammalian histamine H4 receptors have been cloned and characterized. These recombinant molecules are capable of expressing biologically active histamine H4 receptor protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The pharmacology of known histamine ligands is demonstrated. The recombinant protein may be purified from the recombinant host cells. In addition, recombinant host cells are utilized to establish methods to identify modulators of the receptor activity, and receptor modulators are identified.

DNAs encoding rat histamine receptors of the H4 subtype

DNAs encoding mammalian histamine receptor of the H4 subtype and encoded protein

DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Methods of use of DNA encoding a human histamine receptor of the H3 subtype

A transgenic animal with alterations in the histamine H3 receptor gene is prepared by introduction of an altered histamine H3 receptor gene into a host animal. The resulting transgenic animals do not produce functional histamine H3 receptor molecules. Cells and cell lines derived from these animals also contain the altered histamine H3 receptor gene.

Histamine receptor H3 modified transgenic mice

DNAs encoding guinea pig histamine receptors of the H4 subtype

Growing community of inventors

San Diego, CA, United States of America

Timothy W Lovenberg